<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>NKTR Shares Surge 38.2% in a Week: Here's What You Should Know</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>NKTR Shares Surge 38.2% in a Week: Here's What You Should Know</h1>
  <ul>
<li>Year to date, shares of Nektar have surged 188.1% compared with the industry’s rise of 14.1%.</li>
<li>The company expects to advance rezpeg into phase III development in the first half of 2026.</li>
<li>Shares of Nektar Therapeutics NKTR have rallied 38.2% in the past week due to growing investor optimism related to the company’s lead pipeline candidate, rezpegaldesleukin (rezpeg), which is being developed as a self-adm</li>
<li>Image Source: Zacks Investment Research NKTR’s Atopic Dermatitis Data on Rezpeg In June 2025, NKTR announced that the phase IIb REZOLVE-AD study evaluating rezpeg in patients with moderate-to-severe atopic dermatitis met</li>
<li>Despite amlitelimab meeting all primary and key secondary endpoints in the COAST 1 study, shares of SNY tanked as the data seemed to fall short of investors' expectations.</li>
<li>Here’s Why NKTR Was Up This Past Week Nektar’s price rose after French drugmaker Sanofi SNY announced data from the phase III COAST 1 study evaluating its pipeline candidate, amlitelimab, for treating moderate-to-severe</li>
<li>However, rezpeg’s long-term efficacy is yet to be determined.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/nktr-shares-surge-38-2-152700121.html">Source</a> · 2025-09-08T15:27:00+00:00</p>
</body>
</html>